Report cover image

Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) - Global Clinical Trials Review, 2025

Publisher GlobalData
Published Oct 29, 2025
SKU # GBDT20601992

Description

Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) - Global Clinical Trials Review, 2025

Summary

GlobalData's clinical trial report, “Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) - Global Clinical Trials Review, 2025 provides an overview of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)
Oct 20, 2025: Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Poster at AASLD The Liver Meeting 2025
Oct 15, 2025: Rivus Pharmaceuticals To Present Clinical Data From Phase 2A M-ACCEL Trial of HU6 in MASH as Late-Breaker Oral Presentation at AASLD 2025
Oct 07, 2025: Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting 2025
Oct 07, 2025: Akero Therapeutics To Present New Data From the Phase 2B Symmetry and Harmony Studies of Efruxifermin at the 76th Annual AASLD the Liver Meeting 2025
Oct 07, 2025: Sagimet Biosciences Announces Upcoming Presentation at AASLD—the Liver Meeting 2025
Oct 07, 2025: Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
Oct 06, 2025: Eccogene Receives U.S. FDA Clearance To Initiate Phase 2A Mosaic Trial of ECC4703 for MASH
Oct 06, 2025: Eccogene Receives U.S. FDA Clearance To Initiate Phase 2A MOSAIC Trial of ECC0509 for MASH
Oct 01, 2025: Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
Sep 17, 2025: Positive Phase 3 Results for Denifanstat for the Treatment of Moderate To Severe Acne To Be Presented at the EADV Congress 2025 by Partner Ascletis
Sep 02, 2025: Biomed Industries to Present Pivotal Studies on NA-931 at Paris MASH 2025 with Breakthrough in Obesity and Liver Disease Therapies
Sep 02, 2025: Biomed Industries to Present Pivotal Studies on NA-941 at Paris MASH 2025 with Breakthrough in Obesity and Liver Disease Therapies
Aug 14, 2025: Akero Announces Publication of Phase 2b Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Aug 12, 2025: Sen-Jam Pharmaceutical Positions SJP-002C as a Transformative Complement to GLP-1 Therapies and a Standalone Solution for MASH
Aug 11, 2025: Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Source
List of Tables
Table 1: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials by Region, 2025*
Table 2: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
Table 3: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
Table 4: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2025*
Table 5: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Europe, Top Five Countries, 2025*
Table 6: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, North America, Top Countries, 2025*
Table 7: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2025*
Table 8: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2025*
Table 9: Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2025*
Table 10: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
Table 11: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
Table 12: Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2025*
Table 13: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
Table 14: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
Table 15: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials by Phase, 2025*
Table 16: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials In Progress by Phase 2025*
Table 17: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2025*
Table 18: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2025*
Table 19: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
Table 20: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2025*
Table 21: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
Table 22: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
Table 23: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
List of Figures
Figure 1: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials by Region (%), 2025*
Figure 2: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
Figure 3: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
Figure 4: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2025*
Figure 5: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2025*
Figure 6: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, North America, Top Countries (%), 2025*
Figure 7: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2025*
Figure 8: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2025*
Figure 9: Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2025*
Figure 10: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
Figure 11: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
Figure 12: Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2025*
Figure 13: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
Figure 14: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
Figure 15: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials by Phase (%), 2025*
Figure 16: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials In Progress by Phase, 2025*
Figure 17: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2025*
Figure 18: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2025*
Figure 19: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
Figure 20: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2025*
Figure 21: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
Figure 22: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
Figure 23: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
Figure 24: GlobalData Methodology

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us